Adam Friedman, MD, FAAD is an associate professor of dermatology and serves as residency program director and director of translational research in the department of dermatology at the George Washington University School of Medicine & Health Sciences.
Dr. Friedman completed his undergraduate training at the University of Pennsylvania and graduated with distinction in dermatologic research at the Albert Einstein College of Medicine in New York. He completed his internship at New York Hospital Queens and returned to Einstein for his dermatology residency and was appointed chief resident during his final year. Dr. Friedman joined the Einstein faculty after graduation from 2010-2015, during which time he was the director of dermatologic research, director of the translational research fellowship, and the associate program director.
Dr. Friedman is currently investigating novel nanotechnologies that allow for controlled and sustained delivery of a wide spectrum of physiologically and medicinally relevant molecules, with an emphasis on treating infectious diseases, accelerating wound healing, immune modulation and correcting vascular dysfunction. He holds multiple patents derived from these investigations, and has published over 120 papers/chapters and 2 textbooks on both his research as well as a variety of clinical areas in dermatology with an emphasis on emerging medical therapies. In line with his research interests, he serves as Vice President of the nanodermatology society and vice chair of the dermatology section of the New York Academy of Medicine.
He has received multiple awards such as the American Dermatologic Association Young Leader Award, the American Society for Dermatologic Surgery Cutting Edge Research Award, the Journal of Drugs in Dermatology Leader in Photoprotection award, the La Roche Posay North American Foundation Research award, and he was voted to New York Times Magazine’s Super Doctors® Rising Stars each year since 2013. Dr. Friedman is also committed to resident and medical education. He chaired of the leadership workgroup of the American Academy of Dermatology Resident/Fellows Committee, currently serves on the Sulzberger Committee on Education, and is the senior editor of the Dermatology In-Review Online Workshop. Dr. Friedman serves as the dermatology expert for healthguru.com, publishes a column on Everyday Health entitled "The Skin You're In" and in line with his research interests, as the vice president of the Nanodermatology Society. Dr. Friedman was recently appointed as President of the Dermatology Section of the New York Academy of Medicine.
Dr. Friedman has appeared on television news programs such as Good Morning America, and has been quoted in numerous leading publications, including WebMD, In Style, Reuters, Good Housekeeping, and Women’s Day.
- Appropriately diagnose patients with collagen vascular diseases
- Develop a treatment algorithm that incorporates modalities including sun protection and topical therapies
- Describe associated systematic complications with collagen vascular diseases and screen appropriately
- New advances in dermatologic treatment
- New methods of diagnosis or treatment
- Advances in medical knowledge
- Schairer D, Friedman A. “Manifestations and Treatment of Cutaneous Lupus Erthematosus.” J Drugs Dermatol. 2011; 10(10): 1212-1214.
- Fett N, Werth VP. “Update on Morphea.” J Am Acad Dermatol. 2011; 64(2):: 217-28.
- Andrews Diseases of the Skin. 11th Edition.
- Dermatology. 3rd Edition 2012 Elsevier.
Core Competency: 1, 2, 3, 4, 6
Speaker/Faculty Education for: Amgen, Onset Dermatologics, Orlando Dermatology Aesthetic & Clinical, Valeant Pharmaceuticals
Consultant for: Encore Dermatology, Inc., Galderma, GlaxoSmithKline, IntraDerm, Johnson & Johnson, Liquidia Technologies, Inc., Oculus Innovative, Onset Therapeutics, Pfizer, Sanova Works
Advisory Board: Amgen, Biogen, La Roche-Posay Laboratorie Pharmaceutique, Nerium International, Novartis, Salvona Technologies, LLC, Valeant Pharmaceuticals
Principal Investigator: Valeant Pharmaceuticals, Dermatology Foundation, Janssen-Ortho Inc.
VP/Board Member: Nanodermatology Society